tert-Butyl 4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indazol-6-yl)piperidine-1-carboxylate

Catalog No. :
ACSQWA411
CAS No. :
2654822-21-4
Molecular Formula :
C22H29N5O4
Molecular Weight :
427.51

IUPAC Name:tert-butyl 4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indazol-6-yl)piperidine-1-carboxylate

tert-Butyl 4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indazol-6-yl)piperidine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indazol-6-yl)piperidine-1-carboxylate
IUPAC Nametert-butyl 4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indazol-6-yl)piperidine-1-carboxylate
Molecular FormulaC22H29N5O4
Molecular Weight427.51
SMILESO=C(N1CCC(CC1)C2=CC3=C(C(N4C(NC(CC4)=O)=O)=NN3C)C=C2)OC(C)(C)C
InChI KeyRRDIJSLVQUZSKC-UHFFFAOYSA-N
Synonym1,1-Dimethylethyl 4-[1-methyl-3-(tetrahydro-2,4-dioxo-1(2H)-pyrimidinyl)-1H-indazol-6-yl]-1-piperidinecarboxylate;tert-butyl 4-[3-(2,4-dioxohexahydropyrimidin-1-yl)-1-methylindazol-6-yl]piperidine-1-carboxylate;tert-Butyl 4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H-indazol-6-yl)piperidine-1-carboxylate
CAS No.2654822-21-4

Synthetic Route by SureRoute

1. ACSQWA411 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACSQWA411 route product structure diagram
    ACSQWA4112654822-21-4
Inquiry

2. ACSQWA411 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACDXQY760 route compound structure diagram
    ACDXQY760504-07-4 In Stock
  4. Then
  5. ACSQWA411 route product structure diagram
    ACSQWA4112654822-21-4
Inquiry

Comments (0)